{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:17:00Z","timestamp":1787325420750,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.euroneuro.2014.08.001","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T16:30:17Z","timestamp":1407774617000},"page":"1578-1590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Guanfacine for attention deficit and hyperactivity disorder in pediatrics: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Simona","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5536-4192","authenticated-orcid":false,"given":"Antonio","family":"Clavenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Reale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Bonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.08.001_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2654","article-title":"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention\u2010Deficit\/Hyperactivity Disorder in Children and adolescents","volume":"128","author":"American Academy of Pediatrics","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders:DSM-IV-TR","author":"American Psychiatric Association","year":"2010"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biopsych.2004.08.019","article-title":"Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions","volume":"57","author":"Arnsten","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.0098","article-title":"alpha2-Adrenergic receptor agonists for the treatment of attention-deficit\/hyperactivity disorder: emerging concepts from new data","volume":"17","author":"Arnsten","year":"2007","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1017\/S1092852900017107","article-title":"Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD","volume":"13","author":"Biederman","year":"2008","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib6","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2006-3695","article-title":"A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"121","author":"Biederman","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib7","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2006-3695","article-title":"A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"121","author":"Biederman","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1460-9568.1991.tb00083.x","article-title":"Noradrenergic control of thalamic oscillation: the role of alpha-2 receptors","volume":"3","author":"Buzsaki","year":"1991","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(13)62229-1","article-title":"How to increase value and reduce waste when research priorities are set","volume":"383","author":"Chalmers","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00213-007-0840-x","article-title":"Efficacy and safety of atomoxetine for attention-deficit\/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis","volume":"194","author":"Cheng","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0011-393X(02)80075-3","article-title":"Public disclosure of clinical trials in children","volume":"63","author":"Clavenna","year":"2002","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/000992280003900102","article-title":"A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder","volume":"39","author":"Connor","year":"2000","journal-title":"Clin. Pediatr. (Phila)"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib13","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Connor","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.1987.tb11220.x","article-title":"Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms","volume":"90","author":"De Sarro","year":"1987","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib16","series-title":"ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation","author":"DuPaul","year":"1998"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib17","unstructured":"European Commission2008. Ethical considerations for clinical trials on medicinal products with the paediatric population. (available at \u3008http:\/\/www.ec.europa.eu\/health\/files\/eudralex\/vol-10\/ethical_considerations_en.pdf\u3009)"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00787-009-0054-3","article-title":"Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis","volume":"19","author":"Faraone","year":"2010","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/1087054709332472","article-title":"Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD","volume":"13","author":"Faraone","year":"2010","journal-title":"J. Atten. Disord."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.clinthera.2013.09.005","article-title":"Guanfacine extended release: a novel treatment for attention-deficit\/hyperactivity disorder in children and adolescents","volume":"35","author":"Faraone","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib21","series-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"1981"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib22","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1523\/JNEUROSCI.22-19-08771.2002","article-title":"Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine","volume":"22","author":"Franowicz","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib23","doi-asserted-by":"crossref","first-page":"b1025","DOI":"10.1136\/bmj.b1025","article-title":"Patients and the public deserve big changes in evaluation of drugs","volume":"338","author":"Garattini","year":"2009","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.euroneuro.2014.08.001_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1471-244X-11-176","article-title":"Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis","author":"Hanwella","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/01.CHI.0000046908.27264.00","article-title":"A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children","volume":"42","author":"Hazell","year":"2003","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib26","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u05f3s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaac.2013.11.009","article-title":"Alpha-2 agonists for attention-deficit\/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy","volume":"53","author":"Hirota","year":"2014","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.1995.5.215","article-title":"Guanfacine for treatment of attention-deficit hyperactivity disorder in boys","volume":"5","author":"Horrigan","year":"1995","journal-title":"J. Child. Adolesc. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00004583-199501000-00013","article-title":"An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder","volume":"34","author":"Hunt","year":"1995","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/cap.1990.1.87","article-title":"Clonidine in child and adolescent psychiatry","volume":"1","author":"Hunt","year":"1990","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-7138(09)60065-0","article-title":"Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial","volume":"24","author":"Hunt","year":"1985","journal-title":"J. Am. Acad. Child. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/cap.2010.0064","article-title":"Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit\/hyperactivity disorder","volume":"21","author":"Kollins","year":"2011","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2014.08.001_bib34","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1111\/j.1365-2125.1980.tb04909.x","article-title":"Differences in psychic performance with guanfacine and clonidine in normotensive subjects","volume":"10","author":"Kugler","year":"1980","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biopsych.2008.10.005","article-title":"Childhood predictors of adult attention-deficit\/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative","volume":"65","author":"Lara","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib36","unstructured":"National Collaborating Centre For Mental Health, 2008. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE, London."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","article-title":"Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response","volume":"165","author":"Newcorn","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib39","article-title":"Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children","volume":"45","author":"Newcorn","year":"1998","journal-title":"Pediatr. Clin. North Am."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib40","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaac.2013.06.006","article-title":"Randomized, double-blind trial of guanfacine extended release in children with attention-deficit\/hyperactivity disorder: morning or evening administration","volume":"52","author":"Newcorn","year":"2013","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/chi.0b013e31815d9af7","article-title":"Clonidine for attention-deficit\/hyperactivity disorder: I. efficacy and tolerability outcomes","volume":"47","author":"Palumbo","year":"2008","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1472-6963-9-95","article-title":"A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit\/hyperactivity disorder (ADHD)","volume":"9","author":"Pohl","year":"2009","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1527-3458.2007.00026.x","article-title":"Guanfacine and guanfacine extended release: treatment for ADHD and related disorders","volume":"13","author":"Posey","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/cap.2013.0028","article-title":"A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit\/hyperactivity and related disorders","volume":"23","author":"Sallee","year":"2013","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3810\/pgm.2010.09.2204","article-title":"The role of alpha2-adrenergic agonists in attention-deficit\/hyperactivity disorder","volume":"122","author":"Sallee","year":"2010","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/cap.2010.0135","article-title":"Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit\/hyperactivity disorder","volume":"22","author":"Sallee","year":"2012","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.2008.0080","article-title":"Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Sallee","year":"2009","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CHI.0b013e318191769e","article-title":"Guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder: a placebo-controlled trial","volume":"48","author":"Sallee","year":"2009","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","article-title":"A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","author":"Scahill","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib51","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40263-013-0102-x","article-title":"Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology","volume":"27","author":"Sikirica","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib52","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11632920-000000000-00000","article-title":"Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents","volume":"30","author":"Sikirica","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00003495-198631040-00003","article-title":"Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension","volume":"31","author":"Sorkin","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","author":"Tourette\u2019s-Syndrome-Study-Group","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib55","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.euroneuro.2007.06.001","article-title":"Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis","volume":"18","author":"Usala","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/BF00877397","article-title":"Different types of centrally acting antihypertensives and their targets in the central nervous system","volume":"8","author":"van Zwieten","year":"1994","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.euroneuro.2014.08.001_bib57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","article-title":"Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex","volume":"129","author":"Wang","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaac.2011.10.012","article-title":"A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit\/hyperactivity disorder","volume":"51","author":"Wilens","year":"2012","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.08.001_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000118212","article-title":"Electroencephalographic and psychometric assessment of the CNS effects of single doses of guanfacine hydrochloride (Estulic) and clonidine (Catapres)","volume":"14","author":"Yamadera","year":"1985","journal-title":"Neuropsychobiology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14002284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14002284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T16:12:43Z","timestamp":1565712763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14002284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0924977X14002284"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.08.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guanfacine for attention deficit and hyperactivity disorder in pediatrics: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}